Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 29, 2026
Why Is O-I Glass (OI) Stock Down -18.1% Today?

Why Is O-I Glass (OI) Stock Down -18.1% Today?

Key Takeaways

  • O-I Glass shares plunged approximately 18.1% on Wednesday, sliding to around $7.42 after closing at $9.06 in the prior session, following a deeply disappointing second-quarter earnings report.
  • The primary catalyst was a massive earnings miss: adjusted EPS of $0.09 came in far below the $0.24 analyst consensus, while revenue of $1.67 billion also missed expectations.
  • Management slashed full-year 2026 and 2027 guidance, cut free cash flow projections to negative territory, and suspended adjusted EPS guidance entirely due to uncertainty in Europe.
  • Europe segment operating profit collapsed from $90 million to just $6 million, with margins compressing to 0.9%, driven by competitive pricing pressure and elevated energy costs.
  • A staggering $873 million non-cash goodwill impairment charge was recorded, pushing the company to a net loss of $972 million for the quarter.
  • Traders are now watching whether the company's Fit To Win cost-cutting program can stabilize operations and whether European market conditions show any signs of improvement.

Opening Summary

OI, the stock of O-I Glass, Inc.—one of the world's leading manufacturers of glass bottles and jars serving the food, beverage, wine, spirits, and pharmaceutical industries—suffered a punishing sell-off on Wednesday, tumbling roughly 18.1% to approximately $7.42. The plunge came after the Perrysburg, Ohio-based company reported second-quarter 2026 results that missed analyst estimates across virtually every metric and issued deeply disappointing guidance revisions. The prior session's close stood at $9.06, and the stock is now trading near its 52-week low.

Q2 Earnings Miss: A Tale of Two Continents

The company released its second-quarter results after the market closed on Tuesday, and the numbers painted a starkly divided picture. Adjusted earnings per share came in at just $0.09, an 83% decline from $0.53 in the same quarter a year ago and well below the $0.24 consensus estimate. Revenue of $1.67 billion slipped 2.2% year-over-year and narrowly missed the $1.68 billion that analysts had projected.

While the Americas segment delivered a strong performance—segment operating profit surged 22% to $165 million and margins expanded from 14.3% to 17.4%—Europe completely unraveled. European segment operating profit plummeted from $90 million to a meager $6 million, with margins shrinking from 12.1% to just 0.9%. Management attributed the European weakness to competitive pricing headwinds, elevated energy costs tied to geopolitical tensions in the Middle East, and operational disruptions from restructuring activities and two furnace events.

Guidance Cuts and Suspended Outlook

Perhaps even more alarming for investors than the dismal quarterly results was the sweeping guidance revision. O-I Glass lowered its full-year 2026 adjusted EBITDA forecast to a range of $1.0 billion to $1.1 billion, down from the prior range of approximately $1.125 billion to $1.225 billion. The company also revised its 2027 adjusted EBITDA target downward to $1.2 billion to $1.3 billion, compared to the previous target of $1.45 billion.

In a particularly troubling sign, management now expects free cash flow to turn negative—projecting a range of negative $50 million to $150 million for the full year, a significant reversal from the prior forecast of positive $50 million to $150 million. Additionally, the company suspended its adjusted earnings per share guidance entirely, citing "uncertainty around operating earnings in Europe," a move that underscored how little visibility management has into the near-term trajectory of its European business.

Goodwill Impairment Magnifies the Damage

The headline net loss of $972 million, or $6.33 per share, was dramatically inflated by an $873 million non-cash goodwill impairment charge and a $96 million adjustment to Europe's deferred tax valuation allowance. The company acknowledged that both charges were "driven by the decline in the company's share price, lower current-period results, and a revised future outlook for Europe." While these are non-cash items, they reflect the deteriorating fundamentals and diminished expectations for the European business, reinforcing the bearish narrative that has weighed on OI for months.

Market Context and Trading Activity

Trading volume in OI shares surged well above its daily average of roughly 2.6 million shares, reflecting the intensity of the sell-off as investors rushed to reprice the stock. The move pushed shares to levels not seen since the depths of the pandemic-era sell-off, breaching all major moving averages. The stock's 50-day moving average had been around $9.06 and its 200-day moving average near $11.23—both now far above current trading levels.

The broader materials and industrials sector showed mixed performance on Wednesday, indicating that the OI sell-off was overwhelmingly company-specific rather than sector-driven. The stock had already declined roughly 39% year-to-date heading into the earnings report, and Wednesday's drop compounds what has been a punishing year for shareholders.

What Comes Next for OI

The path forward for O-I Glass hinges largely on whether European market conditions stabilize. CEO Gordon Hardie described the European challenges as "temporary," and the company's Fit To Win cost-reduction program has demonstrated tangible results in the Americas. However, with competitive pricing pressures showing no immediate signs of easing and energy costs remaining elevated, the timeline for a European recovery remains uncertain.

Investors will be closely monitoring the company's upcoming quarterly updates for any evidence that European volumes and pricing are bottoming. The suspension of EPS guidance leaves the market with fewer benchmarks to measure progress, which could contribute to continued volatility in OI shares. Key risks include the company's elevated debt load—long-term debt stands near $4.8 billion—and the possibility that macroeconomic headwinds in Europe persist longer than management anticipates.

Trending AI Robots

In volatile market environments like the one surrounding OI, traders increasingly turn to AI-driven tools for timely analysis. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers across multiple strategies, timeframes, and performance metrics. Only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. Each bot varies by strategy—from swing trading to trend following—allowing traders to find approaches aligned with their goals. Explore the Trending AI Robots page to see which strategies are outperforming right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OI

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


OI's Indicator enters downward trend

The Aroon Indicator for OI entered a downward trend on October 05, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator formed such a pattern. In 176 of the 222 cases the stock moved lower. This puts the odds of a downward move at 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OI as a result. In 72 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for OI turned negative on September 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 19 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where OI advanced for three days, in 185 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.319) is normal, around the industry mean (6.558). P/E Ratio (6.143) is within average values for comparable stocks, (25.090). Projected Growth (PEG Ratio) (0.349) is also within normal values, averaging (1.023). OI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.028). P/S Ratio (0.148) is also within normal values, averaging (1.259).

The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. OI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.

Industry description

The containers/packing sector includes companies that manufacture containers (like plastic and aluminum food containers, glass bottles, metal cans, cardboard, storage and waste bags, giftwraps etc.) and provide packing services. Food-and-beverage and household products are major markets for this business. Several companies in this industry cater to international markets in addition to serving domestic customers. Consumer spending habits could potentially affect this industry’s performance. Some products, that use oil-based materials as inputs, are likely to see their costs of production get impacted (to some extent) by energy price movements. The ever-expanding e-commerce market has only supercharged the amount/frequency of goods shipped domestically and across borders, thereby creating ample potential opportunities for containers and packaging businesses. Ball Corporation, International Paper Company, Amcor Plc and Packaging Corporation of America are some of the largest U.S. companies in this industry.

Market Cap

The average market capitalization across the Containers/Packaging Industry is 6.85B. The market cap for tickers in the group ranges from 6.74K to 66.8B. STO holds the highest valuation in this group at 66.8B. The lowest valued company is EPTI at 6.74K.

High and low price notable news

The average weekly price growth across all stocks in the Containers/Packaging Industry was -2%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 3%. YHGJ experienced the highest price growth at 7%, while DSS experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Containers/Packaging Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was 0% and the average quarterly volume growth was -29%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 38
P/E Growth Rating: 57
Price Growth Rating: 57
SMR Rating: 70
Profit Risk Rating: 86
Seasonality Score: 28 (-100 ... +100)
View a ticker or compare two or three
OI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of glass and plastic packaging products

Industry ContainersPackaging

Industry
Containers Or Packaging
Address
One Michael Owens Way
Phone
+1 567 336-5000
Employees
19000
Web
https://www.o-i.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.